Specifically, in the context of lung cancer, bone marrow‐derived mesenchymal stem cells secrete LIF, which subsequently engages the LIFR/p‐ERK/pS727‐STAT3 signaling pathway, thereby modulating the balance between EMT and its reverse process, MET [44]. This evidence concerns the gene LIF and lung cancer.